Biopharmaceutical Manufacturing, Upstream, Downstream processing news

Headlines

EMA on J&J COVID-19 vaccine: benefit-risk analysis remains positive; possible link with very rare cases of blood clots

The European Medicines Agency’s safety committee (PRAC) says a warning about unusual blood clots with low blood platelets should be added to the product information for COVID-19 Vaccine Janssen: but says the benefit-risk analysis for the vaccine remains positive.

Emergent told to halt manufacturing while FDA inspects its COVID-19 vaccine facility

Emergent BioSolutions, a contract development and manufacturing organization (CDMO), has agreed with the US FDA not to manufacture any new COVID-19 vaccine materials at its Bayview facility in Baltimore, Maryland, while the regulator investigates the...

Content provided by PharmaNutra Spa

Chronic COVID syndrome: a new study shows the positive effects of using Apportal, a targeted nutritional supplement

An investigation was recently conducted in Italy on around 200 post-Covid patients suffering from persistent fatigue, who were advised to take Apportal for 28 days

From biosimilars to process intensification: 5 key trends in the biopharma space today

Efficiency in the biopharmaceutical space has never been more top-of-mind. The COVID-19 pandemic brought an unprecedented urgency to R&D and the key players delivered: Several groups produced a vaccine in record time. To maintain and improve on this...

SparingVision acquires GAMUT Therapeutics; expanding novel ocular disease pipeline

SparingVision will acquire GAMUT Therapeutics, the biotech behind a gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis pigmentosa (RP).

EU adds 100 million doses to Pfizer/BioNTech COVID-19 vaccine order

The European Union has exercised its option, under a previous agreement, to order 100 million additional doses of the Pfizer/BioNTech COVID-19 vaccine, Comirnaty.